vaccine Archives | Be Korea-savvy
S. Korean Bio Firms in Race for COVID-19 Treatment, Vaccine Development

S. Korean Bio Firms in Race for COVID-19 Treatment, Vaccine Development

SEOUL, Oct. 3 (Korea Bizwire) — South Korean pharmaceutical companies have joined the global race to develop vaccines and treatments for the novel coronavirus, and several of them have received approval for clinical trials from the country’s drug safety agency. Among the front-runners is Celltrion Inc.’s antiviral antibody treatment candidate called CT-P59 that is currently [...]

Novavax Reports Second Quarter 2020 Financial and Operational Results

Novavax Reports Second Quarter 2020 Financial and Operational Results

GAITHERSBURG, Md., Aug. 10 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2020. “Novavax’ unprecedented development activities for NVX-CoV2373 and progress continued through the second quarter,” said Stanley C. Erck, [...]

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate

GAITHERSBURG, Md. and MORRISVILLE, N.C., July 23 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and FUJIFILM Diosynth Biotechnologies (FDB), a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today an agreement to manufacture bulk drug substance [...]

Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress

Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress

GAITHERSBURG, Md., July 20 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will present progress of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, at the 2nd International Society for Vaccines Virtual Congress. Dr. Glenn’s presentation will [...]